Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation-Reference-Cited by-同舟云学术

Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation

Published:2021-03-12 Issue:2 Volume:18 Page:979-997
ISSN:1933-7213
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Tavassoly Omid^ORCID,del Cid Pellitero Esther,Larroquette Frederique,Cai Eddie,Thomas Rhalena A.,Soubannier Vincent,Luo Wen,Durcan Thomas M.,Fon Edward A.

Funder

W. Garfield Weston Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13311-021-01017-6.pdf

Reference83 articles.

1. Gill C, Phelan JP, Hatzipetros T, et al. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Sci Rep 2019;9:6724.

2. Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 2017;134:187-205.

3. Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Molecular medicine (Cambridge, Mass) 2008;14:451-464.